Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

NCT02315703 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

393

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: Ad26.Mos.HIV
BIOLOGICAL: MVA-Mosaic
BIOLOGICAL: gp140 DP Low-dose
BIOLOGICAL: gp140 DP High-dose
DRUG: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]